The clearance allows human trials for its one-time treatment targeting a genetic eye disease that causes vision loss.

The firm plans to enroll US patients into the trial of GEB-101 in the second quarter, having launched an investigator-initiated trial in China.

The US Food and Drug Administration (FDA) has cleared GenEditBio Limited’s Investigational New Drug (IND) application to ...

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S.

The cornea is crucial for focusing light onto the retina. When injuries or diseases damage its ability to regenerate new cells, vision can be severely compromised. The new treatment is called ...

A Scots pensioner who "spent half his life in the dark" will be able to see Christmas properly for the first time in years after receiving a life-changing cornea transplant. David Watkins, 72, from ...

Surgeons at Rambam Eye Institute have made medical history. They restored sight to a legally blind patient using a fully 3D printed corneal implant grown entirely from cultured human corneal cells.

Corneal dystrophy without prior surgery appears to be associated with higher rates of depression and anxiety, according to research published in the American Journal of Ophthalmology. This is the ...

University of Iowa researchers have been awarded funding from the National Institutes of Health to explore new ways to prevent or reduce vision loss caused by a degenerative eye disease. Aliasger ...

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...